HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

Benzinga · 03/12 11:22
HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $7 price target.